FindTrial
Sign In

A Comparative Clinical Study to Evaluate the effect of BlaQmax on Subjects with Post COVID-19 symptoms.

A Randomized, Multi Center, Double Blinded, Placebo-Controlled, Parallel-Group, Comparative Clinical Study to Evaluate the effect of BlaQmax on Subjects with Post COVID-19 symptoms.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042782
Enrollment
70
Registered
2022-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: BlaQmax: Oral administration of single dose of BlaQmax 200mg capsules everyday for 84 days Control Intervention1: Placebo: Oral administration of single dose of 200mg Placebo capsules e

Sponsors

Akay Natural Ingredients Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. COVID-19 patients with confirmed diagnosis based on a positive ICMR recognized SARS-Cov-2 test performed >= 4 weeks and 2. Subjects having at least three of the Post COVID-19 symptoms including: [fatigue, headache, respiration problems (dyspnea or polypnea, cough), cognitive disorders (attention, memory, anxiety and depression), pain in joints, muscles and chest, gastrointestinal issues (diarrhea, nausea/vomiting, abdominal discomfort), sleep problems, cardiac issues (chest pain, heart palpitations, tachycardia, arrhythmia]. 3. COVID-19 patients discharged after hospital admission. 4.If female of childbearing age, willing to use an acceptable form of birth control measure, should be stable for past 3 months prior to baseline and throughout the study. 5. Must be willing and able to give informed consent and comply with the study procedures.

Exclusion criteria

Exclusion criteria: 1. Asymptomatic COVID-19 subjects 2. Post COVID-19 patients with symptoms longer than 3 months. 3. Subjects suffering from any uncontrolled chronic health conditions (e.g. diabetes, hypertension, chronic renal failure, heart and liver disease) or other underlying severe diseases (e.g., active bleeding, blood dyscrasias, severe malnutrition) 4. History of any Immunodeficiency disease, Allergy, medication or supplement use that influences the immune system. 5.Patients with malabsorption or gastrointestinal abnormalities which may affect drug absorption

Design outcomes

Primary

MeasureTime frame
Reduction in severity and duration of post covid symptomsTimepoint: Day 0, Day 28 , Day 84—

Secondary

MeasureTime frame
Change in BiomarkersTimepoint: Day 0, Day 84;Change in Cognitive parametersTimepoint: Day 0, Day 84;Change in hematolgical and biochemical parametersTimepoint: Day 0, Day 84;Change in Questionnaire based assessmentsTimepoint: Day 0, Day 28 , Day 84—

Countries

India

Contacts

Public ContactJestin V Thomas

Leads Clinical Research and Bio Services Pvt. Ltd

jestin.leadsclinbio@gmail.com9845125293

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026